title: Targeting matrix metalloproteinases in acute inflammatory shock syndromes.
abstract: The integrity of the vascular wall and its intrinsic basement membrane structures ensure that plasma and the corpuscular elements of the blood remain confined to the intravascular milieu and can enter into the extravascular compartment in a well controlled fashion in cases of tissue infection or inflammation. However, sometimes inflammatory stimuli act on blood leukocytes and on endothelial cells from within the blood vessels and in an overwhelming way, leading to inflammatory shock syndromes. These severe conditions with high mortality rates are characterized by intravascular neutrophil degranulation, permeability changes of endothelia and disintegration of basement membranes and lead to almost uncontrollable edema, coagulation changes and multi-organ failure. Matrix metalloproteinases (MMPs) have been functionally linked with septic and endotoxin shock, with cytokine release syndromes and with acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Here we review a number of association studies, compare inflammatory shock data from gene knockout studies in mice and provide some insights from recent investigations with inhibitors of MMPs. This evaluation strengthens the expectation that MMP inhibitors, in particular those blocking neutrophil proteases, may become useful in the early phase of acute inflammatory shock syndromes.
authors.affiliation: School of Life Science & Technology, China Pharmaceutical University, Nanjing 210009, China.
authors.forename: Zheng
authors.initials: Z
authors.lastname: Qiu
authors.forename: Jialiang
authors.initials: J
authors.lastname: Hu
authors.forename: Philippe E
authors.initials: PE
authors.lastname: Van den Steen
authors.forename: Ghislain
authors.initials: G
authors.lastname: Opdenakker
mesh_terms: D000208:Acute Disease; D000818:Animals; D057166:High-Throughput Screening Assays; D006801:Humans; D007249:Inflammation / Q000188:drug therapy* / Q000201:enzymology / Q000378:metabolism; D061965:Matrix Metalloproteinase Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D020782:Matrix Metalloproteinases / Q000378:metabolism*; D012772:Shock, Septic / Q000188:drug therapy* / Q000201:enzymology; D013329:Structure-Activity Relationship; D013577:Syndrome
chemical_list: D061965:Matrix Metalloproteinase Inhibitors; D020782:Matrix Metalloproteinases